An analysis of the Swedish MG registry suggests that adults with myasthenia gravis (MG) have an impaired quality of life, even when they show low disease activity. Muscle weakness affecting the limbs and breathing primarily drove a diminished quality of life. These findings indicate “an unmet medical need that…
A new Phase 3 clinical trial testing Kyverna Therapeutics’ cell therapy candidate KYV-101 in people with myasthenia gravis (MG) — a study the developer says “supports [a] clear and rapid path to [regulatory approval]” — is expected to start enrolling participants before the end of the year, according to…
Cemdisiran, an under-the-skin injection therapy given every three months, significantly reduced disease activity in people with generalized myasthenia gravis (gMG) after six months of treatment. That’s according to data from the Regeneron Pharmaceuticals-sponsored Phase 3 NIMBLE study (NCT05070858), which evaluated cemdisiran as a monotherapy, as well as…
Treatment with Vyvgart (efgartigimod alfa-fcab) helped reduce the impact of generalized myasthenia gravis (gMG) on activities of daily living among adults who tested negative for antibodies targeting the acetylcholine receptor (AChR) — the most common cause of the disease. That’s according to top-line data from an ongoing Phase 3…
Tapping into PD-1/PD-L1 immune checkpoint proteins — which serve as a kind of natural off switch for an overactive immune response — might help keep myasthenia gravis (MG) under control. That’s according to the findings of a new study from China using immune cells from patients, which suggested that…
Rituximab may be safe and effective in treating women with myasthenia gravis (MG) that’s driven by antibodies that target muscle-specific tyrosine kinase (MuSK), an analysis of patients at a single center in China shows. Significant symptom relief was seen by 90% of patients after a month of treatment and it…
Nine-time tennis Grand Slam champion Monica Seles, who has myasthenia gravis (MG), is teaming up with pharmaceutical company Argenx on a campaign aimed at raising awareness — and increasing understanding — of the rare neuromuscular disease. “I am excited to partner with the Argenx team — to inspire…
Ultomiris (ravulizumab-cwvz) is now closer to being covered by public Canadian healthcare systems when used to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR) — one of its approved indications in the country. That’s according to its developer…
Certain inflammatory molecules known as cytokines may play a role in a person’s risk of developing myasthenia gravis (MG), according to a recent genetic study. The research suggests some of these immune-system signaling molecules could increase the risk of the autoimmune disease, while others might offer protection. The findings, which…
Two genes that help to control the human body’s biological clock are dysregulated in myasthenia gravis (MG) — a disease marked by symptoms that often grow worse throughout the day — according to the findings of a new study from China. Study data indicated that dysregulation of these genes,…
Get regular updates to your inbox.
